In today’s session Bristol-Myers Squibb Co (BMY) recorded an unusually high (462) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the March, 2017 put, expecting serious BMY decrease. With 462 contracts traded and 11714 open interest for the Mar, 17 contract, it seems this is a quite bearish bet. The option with symbol: BMY170317P00052500 closed last at: $3.1 or 4.6% down. The stock increased 1.01% or $0.55 during the last trading session, hitting $55.21. About 14.04M shares traded hands or 18.68% up from the average. Bristol-Myers Squibb Co (NYSE:BMY) has declined 14.93% since March 2, 2016 and is downtrending. It has underperformed by 24.17% the S&P500.
Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on October, 25. They expect $0.63 earnings per share, up 61.54% or $0.24 from last year’s $0.39 per share. BMY’s profit will be $1.07 billion for 21.91 P/E if the $0.63 EPS becomes a reality. After $0.69 actual earnings per share reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -8.70% negative EPS growth.
Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage
Out of 15 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 5 rate it a “Buy”, 3 “Sell”, while 7 “Hold”. This means 33% are positive. Bristol-Myers Squibb Company has been the topic of 33 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was maintained by Jefferies with “Hold” on Tuesday, March 15. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by Citigroup on Tuesday, September 20. The rating was maintained by Jefferies on Thursday, August 27 with “Hold”. On Tuesday, September 29 the stock rating was upgraded by UBS to “Buy”. Jefferies maintained it with “Hold” rating and $80 target price in Thursday, July 14 report. The firm has “Buy” rating by UBS given on Friday, August 19. Credit Suisse maintained Bristol-Myers Squibb Co (NYSE:BMY) on Monday, May 9 with “Outperform” rating. The firm has “Market Perform” rating by BMO Capital Markets given on Monday, January 25. The firm has “Underweight” rating by Atlantic Securities given on Friday, December 18. The rating was upgraded by Berenberg to “Buy” on Friday, January 22.
Insitutional Activity: The institutional sentiment increased to 0.94 in 2016 Q2. Its up 0.01, from 0.93 in 2016Q1. The ratio improved, as 47 funds sold all Bristol-Myers Squibb Co shares owned while 542 reduced positions. 84 funds bought stakes while 472 increased positions. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1.
Osterweis Capital holds 16,668 shares or 0.08% of its portfolio. The Massachusetts-based Penobscot Inv Mgmt has invested 0.38% in Bristol-Myers Squibb Co (NYSE:BMY). Wedgewood Pa last reported 0.29% of its portfolio in the stock. Grimes & Co Inc owns 8,117 shares or 0.08% of their US portfolio. Dixon Hubard Feinour Brown Inc Va has 71,816 shares for 1.69% of their US portfolio. Farmers And Merchants Investments has 0.67% invested in the company for 81,019 shares. Blackrock reported 3.97 million shares or 0.44% of all its holdings. Royal London Asset Management Ltd holds 0.68% or 562,663 shares in its portfolio. Great Lakes Advisors Ltd Liability last reported 119,329 shares in the company. Geneva Advisors Limited Liability has invested 1.59% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Paragon Cap Management Limited Company, a Kansas-based fund reported 4,342 shares. Insight Cap Research And Inc has invested 0.97% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Mariner Wealth Advisors Ltd accumulated 47,938 shares or 0.19% of the stock. Appleton Prtn Incorporated Ma last reported 0.41% of its portfolio in the stock. Cypress Asset Mngmt Tx owns 65,549 shares or 0.96% of their US portfolio.
Insider Transactions: Since May 3, 2016, the stock had 0 insider buys, and 9 selling transactions for $16.83 million net activity. Caldarella Joseph C also sold $255,004 worth of Bristol-Myers Squibb Co (NYSE:BMY) shares. On Friday, May 20 the insider Bancroft Charles A sold $2.14 million. 23,200 shares with value of $1.67M were sold by ANDREOTTI LAMBERTO on Tuesday, June 28. The insider Elicker John E sold $859,219. 34,594 shares with value of $2.47 million were sold by Caforio Giovanni on Tuesday, May 3. The insider LEUNG SANDRA sold 72,544 shares worth $5.11M.
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has a market cap of $93.51 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 32.31 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.